Written by
in
Despite radioligand therapy (RLT) only being approved among patients with metastatic castration-resistant prostate cancer (CRPC) in the post- and pre-chemotherapy settings, Praful Ravi, MB, BChir, MRCP, believes these agents may be integrated…
